CRXT - Clarus begins phase 4 trial of oral testosterone drug Jatenzo for men with kidney disease

Clarus Therapeutics (NASDAQ:CRXT) began screening for the first patient in a phase 4 trial testing its oral drug Jatenzo (testosterone undecanoate) to treat hypogonadal men with chronic kidney disease (CKD). Jatenzo is an androgen approved for testosterone replacement therapy in adult males who have deficient testosterone due to certain medical conditions. Male hypogonadism is a condition that results when the testes do not produce enough testosterone. Men with CKD may experience a fall in testosterone levels as kidney function decreases. The primary goal of the study is to achieve testosterone levels in the normal range after six months of treatment. The company expects results from the trial in H1 2023.

For further details see:

Clarus begins phase 4 trial of oral testosterone drug Jatenzo for men with kidney disease